Inverness, Medarex, Oxford Genome Sciences Ltd. deal

Oxford Genome received access to MEDX's UltiMAb Human Antibody Development System to generate human therapeutic antibodies against cancer targets identified using the Oxford Genome Anatomy Project (OGAP) database. Oxford Genome will have exclusive, worldwide rights to resulting antibodies. MEDX will receive undisclosed license fees and is eligible for milestones and royalties. Under a previous deal, the partners are generating human MAbs against Oxford Genome's colorectal cancer targets (see BioCentury, May 15, 2006). ...